tiprankstipranks
Trending News
More News >
Promising Prospects for Verve Therapeutics: Strong Efficacy and Safety of VERVE-102 Drive Buy Rating
PremiumRatingsPromising Prospects for Verve Therapeutics: Strong Efficacy and Safety of VERVE-102 Drive Buy Rating
2M ago
Verve Therapeutics price target raised to $24 from $18 at Guggenheim
Premium
The Fly
Verve Therapeutics price target raised to $24 from $18 at Guggenheim
2M ago
Cantor upgrades Verve Therapeutics to Overweight after positive data
Premium
The Fly
Cantor upgrades Verve Therapeutics to Overweight after positive data
2M ago
Verve announces initial data from Heart-2 Phase 1b trial of VERVE-102
PremiumThe FlyVerve announces initial data from Heart-2 Phase 1b trial of VERVE-102
2M ago
Verve Therapeutics receives FDA Fast Track designation for VERVE-102
Premium
The Fly
Verve Therapeutics receives FDA Fast Track designation for VERVE-102
2M ago
Biotech stocks slide as Marks resignation seen being negative for sector
Premium
The Fly
Biotech stocks slide as Marks resignation seen being negative for sector
2M ago
Promising Outlook for Verve Therapeutics: FDA Clearance and Strategic Partnership Drive Buy Rating
PremiumRatingsPromising Outlook for Verve Therapeutics: FDA Clearance and Strategic Partnership Drive Buy Rating
2M ago
Verve Therapeutics announces FDA clearance of IND application for VERVE-102
Premium
The Fly
Verve Therapeutics announces FDA clearance of IND application for VERVE-102
2M ago
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital
Premium
The Fly
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100